Skip to main content
SpringerLink
Log in

Prevention of embolism among patients with atrial fibrillation

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hart RG, Halperin JL: Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999, 131:492–501.

    PubMed  CAS  Google Scholar 

  2. Albers GW, Amarenco P, Easton JD, et al.: Anithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001, 119:300S-320S.

    Article  PubMed  CAS  Google Scholar 

  3. Brass LM, Krumholz HM, Scinto JM, Radford M: Warfarin use among patients with atrial fibrillation. Stroke 1997, 28:2382–2389.

    PubMed  CAS  Google Scholar 

  4. Harenberg J, Ingrid J, Tivadar F: Treatment of venous thromboemoblism with the oral thrombin inhibitor, ximelagatran. Israel Med Assoc J 2002, 4:1003–1005.

    CAS  Google Scholar 

  5. Eriksson BI, Bergqvist D, Kalebo P, et al.: Ximelagatran and melagaran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002, 360:1441–1447.

    Article  PubMed  CAS  Google Scholar 

  6. Schulman S, Wahlander K, Lundstrom T, et al., for the THRIVE III Investigators: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003, 349:1713–1721.

    Article  PubMed  CAS  Google Scholar 

  7. Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691–1698.

    Article  CAS  Google Scholar 

  8. Mohr JP, Thompson JP, Lazar RM, et al.: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444–1451.

    Article  PubMed  CAS  Google Scholar 

  9. Ezekowitz MD, Bridgers SL, James KE, et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327:1406–1412.

    Article  PubMed  CAS  Google Scholar 

  10. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003, 146:431–438.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Harold P. Adams Jr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adams, H.P. Prevention of embolism among patients with atrial fibrillation. Curr Neurol Neurosci Rep 5, 9–12 (2005). https://doi.org/10.1007/s11910-005-0017-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-005-0017-0

Keywords

Search

Navigation